Cairncross J G, Eisenhauer E A, Macdonald D R, Rathbone M P, Moore M J, Sawka C A, MacCormick R E, Kerr I G
University of Western Ontario, London, Canada.
Can J Neurol Sci. 1990 Feb;17(1):21-3. doi: 10.1017/s0317167100029966.
The National Cancer Institute of Canada Clinical Trials Group conducted a phase II trial of trimetrexate given in a daily x 5 intravenous bolus schedule every 3 weeks in patients with measurable recurrent anaplastic glioma and limited prior treatment. There were no responses in 14 evaluable patients. We conclude that trimetrexate, given as described, is not an active agent in this disease.
加拿大国家癌症研究所临床试验组对复发的间变性胶质瘤且既往治疗有限、肿瘤可测量的患者进行了一项II期试验，采用每3周一次、每日×5次静脉推注的三甲曲沙给药方案。14例可评估患者均无反应。我们得出结论，按上述方法给药的三甲曲沙在该疾病中并非有效药物。
